• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Hydrus microstent increases outflow in cadaveric human eyes

bySwarup Swaminathan, MDandAndrew Bishara
February 21, 2014
in Ophthalmology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Outflow facility in cadaveric eyes increased from a baseline of 0.28 ± 0.10 µL/min/mmHg to 0.44 ± 0.13 µL/min/mmHg after implantation of the Hydrus microstent (p=0.001).

2. Compared to cadaveric eyes implanted with iStents, eyes implanted with the Hydrus scaffold had a significantly greater increase in outflow facility from baseline (increase of 0.08 vs. 0.16 µL/min/mmHg respectively; p=0.03).

Evidence Rating Level: 2 (Good)

Study Rundown: Glaucoma is the most common cause of irreversible blindness globally. Elevated intraocular pressure (IOP) is the only modifiable risk factor in developing glaucoma. Management of glaucoma includes medical and surgical therapy, with surgical techniques aimed at reducing IOP by increasing the outflow of aqueous humor. Multiple surgical stenting or scaffolding devices have been developed to augment outflow. The iStent is an FDA-approved bypass stenting device, while the Hydrus microstent scaffold is a device that is positioned within Schlemm’s canal and is currently in clinical development. In this study, the authors demonstrated that the Hydrus stent significantly improves outflow through cadaveric human eyes, and substantially more than a combination of two iStents (74% vs. 34%; p=0.03). Outflow resistance was decreased significantly with the Hydrus. Limitations of this study include the high standard deviations due to the relatively small sample size. Nonetheless, these data demonstrate that the Hydrus may be a valuable addition to the glaucoma surgical armamentarium.

Click to read the study in Investigative Ophthalmology & Visual Sciences

Relevant Reading: Micro-invasive glaucoma surgery: current perspectives and future directions

RELATED REPORTS

Heavy smoking is associated with visual field loss in glaucoma

Serum lipid levels are positively associated with intraocular pressure

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

In-Depth [basic science study]: In this study, researchers obtained twelve pairs of eyes from human donors. Eyes were perfused at five different pressures using a saline solution, after which two different devices were implanted in the eyes. In one of the two paired eyes, the Hydrus scaffold was inserted. In the other eye, two iStents were placed within a distance equivalent to the length of the Hydrus scaffold. Outflow facility, which represents the inverse of outflow resistance, was measured in these eyes after the intervention. Outflow facility in cadaveric eyes increased from a baseline of 0.28 ± 0.10 µL/min/mmHg to 0.44 ± 0.13 µL/min/mmHg after implantation of the Hydrus microstent (p=0.001). Compared to cadaveric eyes implanted with iStents, eyes implanted with the Hydrus scaffold had a significantly greater increase in outflow facility from baseline (0.08 vs. 0.16 µL/min/mmHg respectively; p=0.03). Calculated outflow resistance was significantly lower in the Hydrus group. These data appear to suggest that both devices are effective in augmenting outflow of aqueous humor, but that the Hydrus scaffold may actually outperform the iStent device.

More from this author: Argus II retinal prosthesis significantly improves spatial vision in blind patients, Artificial cornea is well retained in patients with ocular surface disease, High prevalence of undiagnosed glaucoma in West Africa, Interferon therapy is superior to methotrexate for uveitis, Rho kinase inhibitor safely reduces intraocular pressure

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: basic science studyglaucomaHydrus Scaffoldintraocular pressureiStentOphthalmology
Previous Post

Malarial transmission substantially reduced in endemic Africa

Next Post

Pleural effusions associated with worse survival in non-small-cell lung cancer

RelatedReports

Smoking during pregnancy associated with aerobic fitness of children
Ophthalmology

Heavy smoking is associated with visual field loss in glaucoma

June 28, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Ophthalmology

Serum lipid levels are positively associated with intraocular pressure

May 10, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

March 9, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Next Post
Afatinib shows increased progression-free survival in non-small-cell lung cancer

Pleural effusions associated with worse survival in non-small-cell lung cancer

Multiple opioid prescriptions associated with higher hospital admissions

Multiple opioid prescriptions associated with higher hospital admissions

Transcatheter aortic valve replacement provides only minor benefit to quality of life

Transcatheter aortic valve replacement provides only minor benefit to quality of life

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.